Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2024 Sep 6:2024.09.06.611640.
doi: 10.1101/2024.09.06.611640.

Antibiotic killing of drug-induced bacteriostatic cells

Affiliations

Antibiotic killing of drug-induced bacteriostatic cells

Teresa Gil-Gil et al. bioRxiv. .

Update in

Abstract

Background: There is a long-standing belief that bacteriostatic drugs are inherently antagonistic to the action of bactericidal antibiotics. This belief is primarily due to the fact that the action of most bactericidal antibiotics requires the target bacteria to be growing. Since bacteriostatic drugs stop the growth of treated bacteria, these drugs would necessarily work against one another. We have recently shown that bacteria treated with high concentrations of bacteriostatic drugs retain some metabolic activity, dividing on average once per day.

Objectives: We seek to determine if this low level of growth is sufficient to allow for bactericidal antibiotics of different classes to still kill after bacteria are treated with bacteriostatic drugs.

Methods: We first treated Escherichia coli and Staphylococcus aureus with two different bacteriostatic drugs, followed by one of three bactericidal drugs of three different classes. The density of these bacteria was tracked over six days to determine the amount of killing that occurred.

Results: Our results question this long-standing belief by demonstrating conditions where sequential treatment with a bacteriostatic then bactericidal antibiotic is as or more effective than treatment with a bactericidal drug alone.

Conclusions: These results raise the need to investigate the pharmacodynamics of the joint action of bacteriostatic and bactericidal antibiotics in vitro and in vivo.

Keywords: Antibiotic Resistance; Antibiotics; Bacteriostasis; Population Biology.

PubMed Disclaimer

Conflict of interest statement

Transparency Declarations The authors have no competing interests to declare.

Figures

Figure 1.
Figure 1.. Exposure to varying concentrations of bacteriostatic drugs for six days without transferring.
Density in CFU/mL of E. coli MG1655 (A and B) and S. aureus MN8 (C and D) measured every day for six days at several concentrations of either chloramphenicol (CHL) (A and C), azithromycin (AZM) (B), or tetracycline (TET) (D). Shown in black for each panel is a control culture without antibiotics.
Figure 2.
Figure 2.. The treatment of E. coli and S. aureus with bacteriostatic followed by bactericidal antibiotics.
Shown are bacterial densities in CFU/mL, each point represents the mean and standard deviation of three biological replicates. Cultures are sampled every day for six days and are not transferred. A, B, and C correspond to E. coli experiments and D, E, and F to S. aureus experiments. Chloramphenicol is at 4× MIC, azithromycin at 4× MIC, tetracycline is at 10× MIC, and the bactericidal drugs are all at 4× MIC for E. coli and 12× MIC for S. aureus. For panels A, B, D, and E cultures were treated with either chloramphenicol, azithromycin, or tetracycline for one day before the subsequent addition of a bactericidal antibiotic. Figure C and F are a control where cultures were treated with only a bactericidal or bacteriostatic drug.

References

    1. Nemeth J, Oesch G, Kuster SP. Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis. J Antimicrob Chemother 2015; 70(2): 382–95. - PubMed
    1. Wald-Dickler N, Holtom P, Spellberg B. Busting the Myth of “Static vs Cidal”: A Systemic Literature Review. Clin Infect Dis 2018; 66(9): 1470–4. - PMC - PubMed
    1. Liu J, Shu Y, Zhu F, et al. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis. J Glob Antimicrob Resist 2021; 24: 136–47. - PubMed
    1. Ocampo PS, Lázár V, Papp B, et al. Antagonism between bacteriostatic and bactericidal antibiotics is prevalent. Antimicrob Agents Chemother 2014; 58(8): 4573–82. - PMC - PubMed
    1. Morales-Durán N, León-Buitimea A, Morones-Ramírez JR. Unraveling resistance mechanisms in combination therapy: A comprehensive review of recent advances and future directions. Heliyon 2024; 10(6): e27984. - PMC - PubMed

Publication types

LinkOut - more resources